Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2014-12-08FDA Approved: OLANZAPINE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for a generic olanzapine product from Aurobindo Pharma Limited.
-
FDA approval · 2014-12-08FDA Approved: OLANZAPINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for olanzapine submitted by Teva Pharmaceuticals USA, Inc.
-
FDA approval · 2014-12-08FDA Approved: OLANZAPINE — Supplemental Application (Jubilant Cadista Pharmacuticals Inc.)
FDA approves Jubilant Cadista Pharmaceuticals Inc.'s supplemental application for olanzapine, enabling a generic olanzapine product.
-
CLINICAL_TRIALS research · 2014-12-05Clinical Trial Update: Cognitive Remediation in Schizophrenia [NA]
A clinical trial update from University of Dublin on cognitive remediation in schizophrenia. The status of the trial is not disclosed.
-
CLINICAL_TRIALS trial_result · 2014-12-04Clinical Trial Update: 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated [Phase 4]
A Phase 4 study in adults diagnosed with schizophrenia that includes incarcerated individuals completed, with results posted in December 201…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2014-12-03Clinical Trial Update: Metabolic Syndrome in Patients With First-episode Schizophrenia
Completed clinical trial update investigating metabolic syndrome in patients with first-episode schizophrenia. The snippet does not provide …
-
FDA approval · 2014-11-28FDA Approved: RISPERIDONE — Supplemental Application (Natco Pharma USA LLC)
The FDA approved a supplemental application for risperidone from Natco Pharma USA LLC under an ANDA, enabling continued marketing of a gener…
-
CLINICAL_TRIALS trial_result · 2014-11-20Clinical Trial Update: A Twelve Week, Open Label Extension Study in Patients With Schizophrenia [Phase 3]
A twelve-week open-label extension study (Phase 3) in schizophrenia was completed with results posted in 2014.
-
CLINICAL_TRIALS trial_result · 2014-11-20Clinical Trial Update: An Open Trial of Cysteamine Treatment in Schizophrenia [NA]
An open-label clinical trial of cysteamine for schizophrenia (also studied for schizoaffective disorder) was terminated, with results posted…
-
CLINICAL_TRIALS trial_result · 2014-11-19Clinical Trial Update: POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia [Phase 2]
A Phase 2 proof-of-concept trial evaluated adding pipamperone to stable risperidone or paliperidone therapy in chronic schizophrenia (also r…
-
CLINICAL_TRIALS trial_result · 2014-11-19Clinical Trial Update: Effectiveness of Ziprasidone for Patients With Schizophrenia [Phase 4]
Phase 4 clinical trial update evaluating the effectiveness of ziprasidone for patients with schizophrenia, with schizoaffective disorder als…
-
FDA approval · 2014-11-18FDA Approved: SAPHRIS — Supplemental Application (Allergan, Inc.)
The FDA approved Allergan's supplemental application for SAPHRIS (asenapine) to update its labeling, reflecting an expanded or clarified ind…
-
CLINICAL_TRIALS trial_result · 2014-11-14Clinical Trial Update: Effects of Metformin and Fish Oil on Treatment With Clozapine [Phase 4]
Phase 4 clinical trial on the effects of adding metformin and fish oil to clozapine in schizophrenia/schizoaffective disorder; study termina…
-
FDA approval · 2014-11-12FDA Approved: INVEGA SUSTENNA — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for INVEGA SUSTENNA (paliperidone palmitate) submitted by Janssen Pharmaceuticals, Inc.
-
CLINICAL_TRIALS trial_result · 2014-11-11Clinical Trial Update: Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia [Phase 3]
Phase 3 clinical trial update of an intramuscular depot formulation of aripiprazole used as maintenance treatment in schizophrenia; results …
-
CLINICAL_TRIALS trial_result · 2014-11-10Clinical Trial Update: Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder [Phase 1]
Phase 1 pharmacokinetic and safety study of LY03004 in stable schizophrenia or schizoaffective disorder patients has completed.
-
FDA label_change · 2014-11-06FDA Approved: QUETIAPINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for quetiapine by Teva Pharmaceuticals USA, Inc., resulting in labeling updates for the product. The…
-
CLINICAL_TRIALS trial_result · 2014-11-06Clinical Trial Update: Diabetes in Neuropsychiatric Disorders [Phase 1, Phase 2]
An NIDDK-sponsored Phase 1/2 trial investigating diabetes in neuropsychiatric disorders with schizophrenia has completed, with results poste…
-
CLINICAL_TRIALS trial_result · 2014-11-04Clinical Trial Update: Cerebral Reorganization in Schizophrenia [NA]
This entry indicates that the clinical trial NCT01781000 evaluating cerebral reorganization in schizophrenia has completed.
-
CLINICAL_TRIALS trial_result · 2014-11-03Clinical Trial Update: Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant [Phase 1]
Phase 1 pharmacokinetic study evaluating risperidone and its active metabolite (9-hydroxy risperidone) when risperidone is administered from…
-
CLINICAL_TRIALS trial_result · 2014-10-31Clinical Trial Update: Treatment Study for Cognitive Deficits in Schizophrenia [Phase 2]
Phase 2 clinical trial evaluating a treatment for cognitive deficits in schizophrenia has completed, and results were posted in 2014.
-
FDA approval · 2014-10-30FDA Approved: QUETIAPINE — Supplemental Application (Accord Healthcare Inc.)
FDA approved Accord Healthcare Inc.'s supplemental application for quetiapine, enabling the marketing of a generic quetiapine product. The a…
-
FDA approval · 2014-10-30FDA Approved: ZYPREXA RELPREVV — Supplemental Application (H2-Pharma LLC)
FDA approved a supplemental application for ZYPREXA RELPREVV (olanzapine pamoate) submitted by H2-Pharma LLC, likely resulting in changes to…
-
CLINICAL_TRIALS trial_result · 2014-10-29Clinical Trial Update: Brief Culturally Adapted Cognitive Behavior Therapy for Psychosis [NA]
The trial evaluating Brief Culturally Adapted Cognitive Behavior Therapy for Psychosis in schizophrenia has completed.
-
FDA approval · 2014-10-28FDA Approved: QUETIAPINE FUMARATE — Original Application (Alembic Pharmaceuticals Limited)
FDA approved Alembic Pharmaceuticals Limited's original generic application for quetiapine fumarate, a second-generation antipsychotic used …